Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 21, Art. 66 (pp. 819-828)    |    2020       
»

Toxicity of antiretroviral drugs for the treatment of hiv infection
Kirov Military Medical Academy Russian Federation Defense Ministry, Saint-Petersburg, Russia.



Brief summary

The review discusses the main toxic effects of nucleoside reverse transcriptase inhibitors of human immunodeficiency virus (HIV), which are most often used in antiretroviral therapy regimens for HIV infection. The need for continuous monitoring of antiretroviral therapy in different directions, including the study of clinical and toxic effects (since not all events are recognized, and not all recognized events are reported) has been shown.


Key words

HIV infection, young people, antiretroviral drugs, toxicity, treatment, prophylaxis.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Federalnii naychno-metodicheskii centr po profilaktike i borbe so SPIDom FBYN Centralnogo NII epidemiologii Rospotrebnadzora. Spravka «VICh-infekciya v Rossiiskoi Federacii v pervom polygodii 2019 g.». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (data obrasheniya: 16.02.2020).


2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection // J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa


3. Bartlett K., Eaton S. Mitochondrial beta-oxidation // Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x


4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat // J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002


5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases // Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783


6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria // AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002


7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs // J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x


8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage // Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418


9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.


10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111


11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity // Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3


12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective // Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201


13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection // Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4


14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790


15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity // Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8


16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection // New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301


17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy // AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009


18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors // Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d


19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection // J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.


20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment // Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005





References


1. Federal Scientific and Methodological Center for the Prevention and Control of AIDS of the Central Federal Research Institution of Epidemiology of Rospotrebnadzor. Enquiry «HIV infection in the Russian Federation in the first half of 2019». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (date of the application: 16.02.2020) [In Russian].


2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection. J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa


3. Bartlett K., Eaton S. Mitochondrial beta-oxidation. Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x


4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002


5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783


6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002


7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x


8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418


9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.


10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111


11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity. Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3


12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201


13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4


14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790


15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8


16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301


17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009


18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d


19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.


20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005





Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100